<?xml version="1.0" encoding="UTF-8"?>
<paload id="uuid-here" version="1.0">
    <toplevel>
        <routedMedId>154218</routedMedId>
        <routedMedName>Prolia subcutaneous</routedMedName>
        <routedGenericName>denosumab subcutaneous</routedGenericName>
        <etcIds>
            <etc_id>6239</etc_id>
        </etcIds>
        <medIds>
            <medId>561413</medId>
        </medIds>
    </toplevel>
    <diagnoses>
        <diagnosis>
            <fqn>Osteoporosis with high risk of fracture (female member)</fqn>
            <icd9>2896</icd9>
            <symbolic>ostfemale</symbolic>
            <rating>labeledDx</rating>
            <genotype/>
            <subtype>
                <name>high risk of fracture</name>
                <dur/>
                <durUnit/>
            </subtype>
            <prescribers>
                <prescriber>
                    <name>Not Appicable</name>
                    <code>Not Applicable</code>
                </prescriber>
            </prescribers>
            <age>
            	<ageRangeType>gt</ageRangeType>
            	<ageRangeMin>18</ageRangeMin>
            	<ageRangeMax></ageRangeMax>	
            	<ageRangeUnit>years</ageRangeUnit> 
            	<ageDesc></ageDesc>           
            </age>
            <gender>f</gender>
            <triedtherapy>
                <criteriaSet>         
                    <patientHxType>
                        <typeName>any</typeName>
                        <treatment/>                       
                    </patientHxType>
                    <preferredTherapy>
                        <treatment>
                            <mustBeIneligible>false</mustBeIneligible>
                            <documentationRequired>true</documentationRequired>
                            <treatmentLine>
                                <option>OR</option>
                                <interventionType>group</interventionType>
                                <codeValues>02.16383|02.1257|02.154925|</codeValues>
                                <selectedListName>oral bisphosphonates</selectedListName>
                                <selectedListClassCode>03.01</selectedListClassCode>
                                <dur>12</dur>
                                <durUnit>months</durUnit>
                                <durModifier>at least</durModifier>
                                <timeframe>no timeframe specified</timeframe>
                                <numRequired>any 2</numRequired>
                            </treatmentLine>
                           </treatment>
                           <treatment>
                            <mustBeIneligible>false</mustBeIneligible>
                            <documentationRequired>false</documentationRequired>
                            <treatmentLine>
                                <option>AND</option>
                                <interventionType>group</interventionType>
                                <codeValues>02.95102|02.94907|02.148235|02.148199</codeValues>
                                <selectedListName>intravenous bisphosphonates</selectedListName>
                                <selectedListClassCode>03.02</selectedListClassCode>
                                <dur>12</dur>
                                <durUnit>months</durUnit>
                                <durModifier>at least</durModifier>
                                <timeframe>no timeframe specified</timeframe>
                                <numRequired>any 2</numRequired>
                            </treatmentLine>
                        </treatment>
                        <numRequired>all</numRequired>
                    </preferredTherapy>
                </criteriaSet>
            </triedtherapy>
            <dosing>
                <text>60 mg subcutaneously once every 6 months</text>
            </dosing>
            <instructions>
                <instruction/>
            </instructions>
            <qlimits>
                <qlimit>
                    <medid>561413</medid>
                    <initPerDayDesc>Not Specified</initPerDayDesc>
                    <initPerIntervalDesc>120mg per 12 months</initPerIntervalDesc>
                    <renewPerDayDesc>Not Specified</renewPerDayDesc>
                    <renewPerIntervalDesc>120mg per 12 months</renewPerIntervalDesc>
                </qlimit>
            </qlimits>
            <durations>
                <initialDur>
                    <dur>12</dur>
                    <durUnit>months</durUnit>
                </initialDur>
                <renewalDur>
                    <dur>12</dur>
                    <durUnit>months</durUnit>
                </renewalDur>
                <overallMax>
                    <dur/>
                    <durUnit/>
                </overallMax>
            </durations>
            <exclusions/>
            <precautions>
                <precaution>
                    <text/>
                    <severity/>
                </precaution>
            </precautions>
        </diagnosis>
        <diagnosis>
            <fqn>Osteoporosis with high risk of fracture (male member)</fqn>
            <icd9>2896</icd9>
            <symbolic>ostmale</symbolic>
            <rating>labeledDx</rating>
            <genotype/>
            <subtype>
                <name>high risk of fracture</name>
                <dur/>
                <durUnit/>
            </subtype>
            <prescribers>
                <prescriber>
                    <name>Not Appicable</name>
                    <code>Not Applicable</code>
                </prescriber>
            </prescribers>
            <age>
            	<ageRangeType>gt</ageRangeType>
            	<ageRangeMin>18</ageRangeMin>
            	<ageRangeMax></ageRangeMax>	
            	<ageRangeUnit>years</ageRangeUnit> 
            	<ageDesc></ageDesc>	            
            </age>
            <gender>m</gender>
            <triedtherapy>
				<criteriaSet>
				    <patientHxType>
				        <typeName>any</typeName>
                        <treatment/>                
                    </patientHxType>
                    <preferredTherapy>
                        <treatment>
                            <mustBeIneligible>false</mustBeIneligible>
                            <documentationRequired>false</documentationRequired>
                            <treatmentLine>
                                <option>OR</option>
                                <interventionType>group</interventionType>
                                <codeValues>02.16383|02.1257|02.154925|02.162097|02.92884|02.1273|02.92883|02.7835</codeValues>
                                <selectedListName>oral bisphosphonates</selectedListName>
                                <selectedListClassCode>03.01</selectedListClassCode>
                                <dur>12</dur>
                                <durUnit>months</durUnit>
                                <durModifier>at least</durModifier>
                                <timeframe>no timeframe specified</timeframe>
                                <numRequired>any</numRequired>
                            </treatmentLine>
                           </treatment>
                           <treatment>
                            <mustBeIneligible>false</mustBeIneligible>
                            <documentationRequired>false</documentationRequired>
                            <treatmentLine>
                                <option>AND</option>
                                <interventionType>group</interventionType>
                                <codeValues>02.95102|02.94907|02.148235|02.148199|02.21754|02.21757</codeValues>
                                <selectedListName>intravenous bisphosphonates</selectedListName>
                                <selectedListClassCode>03.02</selectedListClassCode>
                                <dur>12</dur>
                                <durUnit>months</durUnit>
                                <durModifier>at least</durModifier>
                                <timeframe>no timeframe specified</timeframe>
                                <numRequired>any</numRequired>
                            </treatmentLine>
                        </treatment>
                        <numRequired>all</numRequired>
                    </preferredTherapy>
                </criteriaSet>
            </triedtherapy>
            <dosing>
                <text>60 mg subcutaneously once every 6 months</text>
            </dosing>
            <instructions>
                <instruction/>
            </instructions>
            <qlimits>
                <qlimit>
                    <medid>561413</medid>
                    <initPerDayDesc>Not Specified</initPerDayDesc>
                    <initPerIntervalDesc>120mg per 12 months</initPerIntervalDesc>
                    <renewPerDayDesc>Not Specified</renewPerDayDesc>
                    <renewPerIntervalDesc>120mg per 12 months</renewPerIntervalDesc>
                </qlimit>
            </qlimits>
            <durations>
                <initialDur>
                    <dur>12</dur>
                    <durUnit>months</durUnit>
                </initialDur>
                <renewalDur>
                    <dur>12</dur>
                    <durUnit>months</durUnit>
                </renewalDur>
                <overallMax>
                    <dur/>
                    <durUnit/>
                </overallMax>
            </durations>
            <exclusions/>
            <precautions>
                <precaution>
                    <text/>
                    <severity/>
                </precaution>
            </precautions>
        </diagnosis>        
        <diagnosis>
            <fqn>Long term (current) use of aromatase inhibitors/Malignant neoplasm of breast</fqn>
            <icd9>Z79.811</icd9>
            <symbolic>neobreast</symbolic>
            <rating>labeledDx</rating>
            <genotype/>
            <subtype>
                <name/>
                <dur/>
                <durUnit/>
            </subtype>
            <prescribers>
            </prescribers>
            <age>
            	<ageRangeType>gt</ageRangeType>
            	<ageRangeMin>18</ageRangeMin>
            	<ageRangeMax></ageRangeMax>	
            	<ageRangeUnit>years</ageRangeUnit> 
            	<ageDesc></ageDesc>	            
            </age>
            <gender>nocode</gender>
            <comorbidity>
                <name>Malignant neoplasm of breast</name>
                <icd9>C50</icd9>
                <dur/>
                <durUnit/>
            </comorbidity>
            <triedtherapy>
            </triedtherapy>
            <dosing>
                <text>60 mg subcutaneously once every 6 months</text>
            </dosing>
            <instructions>
                <instruction/>
            </instructions>
            <qlimits>
                <qlimit>
                    <medid>561413</medid>
                    <initPerDayDesc>Not Specified</initPerDayDesc>
                    <initPerIntervalDesc>120mg per 12 months</initPerIntervalDesc>
                    <renewPerDayDesc>Not Specified</renewPerDayDesc>
                    <renewPerIntervalDesc>120mg per 12 months</renewPerIntervalDesc>
                </qlimit>
            </qlimits>
            <durations>
                <initialDur>
                    <dur>12</dur>
                    <durUnit>months</durUnit>
                </initialDur>
                <renewalDur>
                    <dur>12</dur>
                    <durUnit>months</durUnit>
                </renewalDur>
                <overallMax>
                    <dur/>
                    <durUnit/>
                </overallMax>
            </durations>
            <references>
                <reference>National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. http://nof.org/files/nof/public/content/file/2610/upload/895.pdf. Published April 1, 2014. Accessed August 1, 2014.</reference>
                <reference>Watts NB, Adler RA, Bilezikian JP, Drake MT, Eastell R, Orwoll ES, et al. Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:1802-22. (Also available on the Endocrine Society’s website http://www.endo-society.org/guidelines/Current-Clinical-Practice-Guidelines.cfm)</reference>
                <reference>Kanis JA; for World Health Organization Scientific Group. Assessment of osteoporosis at the primary health care level. http://www.shef.ac.uk/FRAX/pdfs/WHO_Technical_Report.pdf. Published 2007.  Accessed August 1, 2014.</reference>
                <reference>Prolia [package insert]. Thousand Oaks, CA: Amgen Inc; 2014</reference>
            </references>
            <exclusions/>
            <precautions>
                <precaution>
                    <text/>
                    <severity/>
                </precaution>
            </precautions>
        </diagnosis>
        <diagnosis>
            <fqn>Long term (current) use of aromatase inhibitors/Malignant neoplasm of prostate non-metastatic</fqn>
            <icd9>Z79.811</icd9>
            <symbolic>neoprostate</symbolic>
            <rating>labeledDx</rating>
            <genotype/>
            <subtype>
                <name/>
                <dur/>
                <durUnit/>
            </subtype>
            <prescribers>
            </prescribers>
            <age>
            	<ageRangeType>gt</ageRangeType>
            	<ageRangeMin>18</ageRangeMin>
            	<ageRangeMax></ageRangeMax>	
            	<ageRangeUnit>years</ageRangeUnit> 
            	<ageDesc></ageDesc>	            
            </age>
            <gender>nocode</gender>
            <comorbidity>
                <name>Malignant neoplasm of prostate</name>
                <icd9>C61</icd9>
                <dur/>
                <durUnit/>
            </comorbidity>
            <triedtherapy>
            </triedtherapy>
            <dosing>
                <text>60 mg subcutaneously once every 6 months</text>
            </dosing>
            <instructions>
                <instruction/>
            </instructions>
            <qlimits>
                <qlimit>
                    <medid>561413</medid>
                    <initPerDayDesc>Not Specified</initPerDayDesc>
                    <initPerIntervalDesc>120mg per 12 months</initPerIntervalDesc>
                    <renewPerDayDesc>Not Specified</renewPerDayDesc>
                    <renewPerIntervalDesc>120mg per 12 months</renewPerIntervalDesc>
                </qlimit>
            </qlimits>
            <durations>
                <initialDur>
                    <dur>12</dur>
                    <durUnit>months</durUnit>
                </initialDur>
                <renewalDur>
                    <dur>12</dur>
                    <durUnit>months</durUnit>
                </renewalDur>
                <overallMax>
                    <dur/>
                    <durUnit/>
                </overallMax>
            </durations>
            <exclusions/>
            <precautions>
                <precaution>
                    <text/>
                    <severity/>
                </precaution>
            </precautions>
        </diagnosis>
    </diagnoses>
    <lists>
        <listDef>
            <name> oral bisphosphonates</name>
            <codeValue>03.01</codeValue>
            <listType>adhoc</listType>
            <listItem>
                <name>Actonel oral</name>
                <codeValue>02.16383</codeValue>
            </listItem>
            <listItem>
                <name>alendronate oral</name>
                <codeValue>02.1257</codeValue>
            </listItem>
            <listItem>
                <name>Atelvia oral</name>
                <codeValue>02.154925</codeValue>
            </listItem>
            <listItem>
                <name>Binosto oral</name>
                <codeValue>02.162097</codeValue>
            </listItem>
            <listItem>
                <name>Boniva oral</name>
                <codeValue>02.92884</codeValue>
            </listItem>
            <listItem>
                <name>Fosamax oral</name>
                <codeValue>02.1273</codeValue>
            </listItem>
            <listItem>
                <name>ibandronate oral</name>
                <codeValue>02.92883</codeValue>
            </listItem>
            <listItem>
                <name>risedronate oral</name>
                <codeValue>02.7835</codeValue>
            </listItem>
        </listDef>
        <listDef>
            <name> intravenous bisphosphonates</name>
            <codeValue>03.02</codeValue>
            <listType>adhoc</listType>
            <listItem>
                <name>Boniva intravenous</name>
                <codeValue>02.95102</codeValue>
            </listItem>
            <listItem>
                <name>ibandronate intravenous</name>
                <codeValue>02.94907</codeValue>
            </listItem>
            <listItem>
                <name>Reclast intravenous</name>
                <codeValue>02.148235</codeValue>
            </listItem>
            <listItem>
                <name>zoledronic acid in mannitol and water intravenous</name>
                <codeValue>02.148199</codeValue>
            </listItem>
            <listItem>
            	<name>zoledronic acid intravenous</name><codeValue>02.21754</codeValue>
            	</listItem>
            <listItem>
            	<name>Zometa intravenous</name>
            	<codeValue>02.21757</codeValue></listItem>
        </listDef>
        <listDef>
            <name>bisphosphonates</name>
            <codeValue>01.176</codeValue>
            <listType>class</listType>
            <listItem>
                <name>Fosamax</name>
                <codeValue>01.1265</codeValue>
            </listItem>
            <listItem>
                <name>risedronate</name>
                <codeValue>01.7510</codeValue>
            </listItem>
            <listItem>
                <name>alendronate</name>
                <codeValue>01.1249</codeValue>
            </listItem>
            <listItem>
                <name>Actonel</name>
                <codeValue>01.15387</codeValue>
            </listItem>
            <listItem>
                <name>zoledronic acid</name>
                <codeValue>01.20382</codeValue>
            </listItem>
            <listItem>
                <name>Zometa</name>
                <codeValue>01.20384</codeValue>
            </listItem>
            <listItem>
                <name>ibandronate</name>
                <codeValue>01.79193</codeValue>
            </listItem>
            <listItem>
                <name>zoledronic acid-mannitol-water</name>
                <codeValue>01.113840</codeValue>
            </listItem>
            <listItem>
                <name>Boniva</name>
                <codeValue>01.79194</codeValue>
            </listItem>
            <listItem>
                <name>Reclast</name>
                <codeValue>01.113876</codeValue>
            </listItem>
            <listItem>
                <name>Atelvia</name>
                <codeValue>01.124640</codeValue>
            </listItem>
            <listItem>
                <name>Binosto</name>
                <codeValue>01.197285</codeValue>
            </listItem>
        </listDef>
    </lists>
</paload>
